Yosuke Osawa, Hironari Kawai, Tomoyuki Tsunoda, Haruki Komatsu, Miku Okawara, Yuriko Tsutsui, Yuichi Yoshida, Shiori Yoshikawa, Taizo Mori, Taiji Yamazoe, Sachiyo Yoshio, Takashi Oide, Ayano Inui, Tatsuya Kanto – 7 April 2021 – Congestive hepatopathy (CH) with chronic passive congestion is characterized by the progression of liver fibrosis without prominent inflammation and hepatocellular damage. Currently, the lack of reliable biomarkers for liver fibrosis in CH often precludes the clinical management of patients with CH.

Xingyuan Xu, Longyun Ye, Qi Zhang, Hang Shen, Shanshan Li, Xiaoyu Zhang, Mao Ye, Tingbo Liang – 7 April 2021

Julia Driscoll, Cody Wehrkamp, Yu Ota, Jonathan N. Thomas, Irene K. Yan, Tushar Patel – 6 April 2021 – Extracellular vesicles (EVs) are a heterogeneous group of biological nano‐sized vesicles that are released from cells and contribute to intercellular communication. Emerging knowledge about their biogenesis, composition, release, and uptake has resulted in broad interest in elucidating their potential roles in disease pathophysiology.

Xiaoxiao Jiang, Hui Qian, Wen‐Xing Ding – 6 April 2021

Wen‐bin Ding, Meng‐chao Wang, Jian Yu, Gang Huang, Da‐peng Sun, Lei Liu, Jia‐ning Zhang, Yuan Yang, Hui Liu, Wei‐ping Zhou, Fu Yang, Sheng‐xian Yuan – 6 April 2021

Dating Sun, Xia Yang, Bin Wu, Xiao‐Jing Zhang, Hongliang Li, Zhi‐Gang She – 6 April 2021

Shan‐Shan Wang, Xinyu Thomas Tang, Minghui Lin, Jia Yuan, Yi Jacky Peng, Xiujuan Yin, GuoGuo Shang, Gaoxiang Ge, Zhenggang Ren, Bo O. Zhou – 4 April 2021

Yi Niu, Ziyou Lin, Arabella Wan, Lei Sun, Shijia Yan, Heng Liang, Siyue Zhan, Dongshi Chen, Xianzhang Bu, Peiqing Liu, Ceshi Chen, Weiling He, Xiongbin Lu, Guohui Wan – 3 April 2021

Tracey G. Simon, Bjorn Roelstraete, Rajani Sharma, Hamed Khalili, Hannes Hagström, Jonas F. Ludvigsson – 2 April 2021

Jacinth Wing‐Sum Cheu, Carmen Chak‐Lui Wong – 2 April 2021 – Hepatocellular carcinoma (HCC) is one of the deadliest cancers because of late symptom manifestation leading to delayed diagnosis, which limits patients with HCC in terms of receiving curative surgical treatment. There are only a few therapeutic options for patients with advanced HCC. The emergence of immune checkpoint inhibitors (ICIs) brings HCC treatment to a stage at which nivolumab, an anti–programmed cell death protein 1 monoclonal antibody, achieves a 20% response rate.